中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
17期
2641-2642,2643
,共3页
聚乙二醇干扰素α-2a%肝炎,丙型,慢性%临床疗效%安全性
聚乙二醇榦擾素α-2a%肝炎,丙型,慢性%臨床療效%安全性
취을이순간우소α-2a%간염,병형,만성%림상료효%안전성
Pegylated interferon-2a%Hepatitis B,hepatitis C,chronic%Clinical curative effect%Safety
目的：探讨聚乙二醇干扰素α-2a（PEG-IFN-α-2a）治疗慢性丙型肝炎的临床疗效和安全性。方法选择170例慢性丙型肝炎患者作为研究对象，采用数字表法随机分为两组，观察组85例采用PEG-IFN-α-2a治疗，对照组85例采用普通干扰素α-2b治疗，比较两组患者的临床疗效及安全性。结果观察组治疗12周、24周以及24周丙氨酸氨基转移酶（ALT）好转率分别为70．59％、80．00％、92．94％，高于对照组的52．94％、62．35％、70．58％（χ2＝5．42、6．71、4．83，均P＜0．05）；观察组治疗12周、24周以及24周HCV-RNA转阴率分别为64．71％、75．29％、91．76％，均明显高于对照组的50．59％、61．18％、70．59％（χ2＝4．28、7．68、6．31，均P＜0．05）；两组不良反应发生率差异无统计学意义。结论 PEG-IFN-α-2a治疗慢性丙型肝炎具有十分显著的疗效，优于普通干扰素α-2b，值得临床广泛推广和应用。
目的：探討聚乙二醇榦擾素α-2a（PEG-IFN-α-2a）治療慢性丙型肝炎的臨床療效和安全性。方法選擇170例慢性丙型肝炎患者作為研究對象，採用數字錶法隨機分為兩組，觀察組85例採用PEG-IFN-α-2a治療，對照組85例採用普通榦擾素α-2b治療，比較兩組患者的臨床療效及安全性。結果觀察組治療12週、24週以及24週丙氨痠氨基轉移酶（ALT）好轉率分彆為70．59％、80．00％、92．94％，高于對照組的52．94％、62．35％、70．58％（χ2＝5．42、6．71、4．83，均P＜0．05）；觀察組治療12週、24週以及24週HCV-RNA轉陰率分彆為64．71％、75．29％、91．76％，均明顯高于對照組的50．59％、61．18％、70．59％（χ2＝4．28、7．68、6．31，均P＜0．05）；兩組不良反應髮生率差異無統計學意義。結論 PEG-IFN-α-2a治療慢性丙型肝炎具有十分顯著的療效，優于普通榦擾素α-2b，值得臨床廣汎推廣和應用。
목적：탐토취을이순간우소α-2a（PEG-IFN-α-2a）치료만성병형간염적림상료효화안전성。방법선택170례만성병형간염환자작위연구대상，채용수자표법수궤분위량조，관찰조85례채용PEG-IFN-α-2a치료，대조조85례채용보통간우소α-2b치료，비교량조환자적림상료효급안전성。결과관찰조치료12주、24주이급24주병안산안기전이매（ALT）호전솔분별위70．59％、80．00％、92．94％，고우대조조적52．94％、62．35％、70．58％（χ2＝5．42、6．71、4．83，균P＜0．05）；관찰조치료12주、24주이급24주HCV-RNA전음솔분별위64．71％、75．29％、91．76％，균명현고우대조조적50．59％、61．18％、70．59％（χ2＝4．28、7．68、6．31，균P＜0．05）；량조불량반응발생솔차이무통계학의의。결론 PEG-IFN-α-2a치료만성병형간염구유십분현저적료효，우우보통간우소α-2b，치득림상엄범추엄화응용。
Objective To investigate the clinical efficacy and safety of the pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C.Methods 170 cases of patients with chronic hepatitis C were included in the study,by using digital table method they were randomly divided into two groups,the observation group of 85 cases were treated with PEG-IFN-alpha-2a therapy,and 85 cases in the control group using ordinary interferon alpha-2b therapy.Curative effect and safety of two groups of patients were compared.Results The obser-vation group treated for 12 weeks,24 weeks and 24 weeks of alanine aminotransferase (ALT)and improvement rate were respectively 70.59%,80%,92.94%,which were higher than that of the control group (52.94%,62.35% and 70.58%)(χ2 =5.42,6.71,4.83,all P<0.05).The observation group for 12 weeks,24 weeks and 24 weeks of HCV-RNA negative rate were 64.71%,75.29%and 91.76%,obviously were higher than the control group of50.59%, 61.18% and 70.59% (χ2 =4.28,7.68,6.31,all P<0.05).Adverse reaction rates were not statistically signifi-cant.Conclusion The pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C has a significant curative effect of PEG-IFN-alpha-2a therapy in chronic hepatitis C,which is better than the ordinary interferon alpha-2b,and is worthy of extensive promotion and application.
